Form 4 INSULET CORP For: Feb 17 Filed by: Singh Prem
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Insulet Corporation (PODD) PT Raised to $310 at BTIG
February 21, 2025 5:09 AM ESTBTIG analyst Marie Thibault raised the price target on Insulet Corporation (NASDAQ: PODD) to $310.00 (from $300.00) while maintaining a Buy rating.
The analyst comments "Insulet reported Q4 revenue of $597.5M (+17% y/y), beating the consensus estimate of $583M and above the top end of the ~$571-$586M guidance range. U.S. Omnipod revenue of $443.7M (+12.4% y/y) was ~$7.5M above consensus of $436.3M while International Omnipod revenue of $142.0 (+33.1% cc y/ y) was ~$2M higher than consensus. Drug Delivery sales were $11.8M (cons. $6.5M). Type 2 patients were >30% of new U.S. starts in Q4... More
